HC Wainwright Analysts Lift Earnings Estimates for INO

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Research analysts at HC Wainwright upped their Q1 2026 earnings estimates for Inovio Pharmaceuticals in a note issued to investors on Monday, March 16th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of ($0.31) per share for the quarter, up from their prior estimate of ($0.34). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($1.05) EPS.

A number of other research analysts have also commented on INO. Oppenheimer reiterated an “outperform” rating on shares of Inovio Pharmaceuticals in a research report on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research report on Monday, December 29th. Finally, Wall Street Zen raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.75.

Inovio Pharmaceuticals Price Performance

INO stock opened at $1.66 on Wednesday. The company has a 50 day moving average price of $1.65 and a 200 day moving average price of $2.03. Inovio Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $2.98. The stock has a market capitalization of $114.69 million, a PE ratio of -0.99 and a beta of 1.70.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Thursday, March 12th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.68. The company had revenue of ($0.07) million for the quarter, compared to analyst estimates of $0.33 million.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of INO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 5,894 shares during the last quarter. Bank of Montreal Can lifted its stake in Inovio Pharmaceuticals by 23.7% in the second quarter. Bank of Montreal Can now owns 57,946 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 11,110 shares during the period. MCF Advisors LLC acquired a new position in Inovio Pharmaceuticals in the third quarter valued at about $26,000. SG Americas Securities LLC bought a new position in Inovio Pharmaceuticals during the third quarter worth about $27,000. Finally, Stephens Inc. AR bought a new position in Inovio Pharmaceuticals during the third quarter worth about $32,000. 26.79% of the stock is owned by institutional investors.

Key Stories Impacting Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright issued mixed but slightly constructive estimate revisions — it modestly raised Q1–Q3 and FY2026 EPS forecasts (FY now -$1.05) while lowering its Q4 2026 view; the firm kept a Neutral rating, so analyst action is only a modest support for the stock.
• Neutral Sentiment: Multiple law firms are issuing reminders about the April 7, 2026 lead‑plaintiff deadline — procedural notices can drive short-term trading volume as eligible shareholders consider joining litigation, but they do not by themselves change merits of the case. INO Deadline: INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
• Negative Sentiment: Pomerantz LLP filed a securities class action against Inovio and certain officers covering purchases between Oct. 10, 2023 and Dec. 26, 2025 — an active filing raises potential liability, discovery risk, and management distraction that investors typically view as negative. Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc.and Certain Officers – INO
• Negative Sentiment: Several national firms (Rosen, Faruqi & Faruqi, Levi & Korsinsky, Holzer & Holzer, Gross Law Firm, etc.) are actively soliciting clients and encouraging lead‑plaintiff motions — the broad legal outreach increases the likelihood of aggregated claims and sustained headline risk. LEVI & KORSINSKY, LLP: APRIL 7, 2026 — DEADLINE TO SEEK LEAD PLAINTIFF ROLE IN INOVIO PHARMACEUTICALS SECURITIES CLASS ACTION

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.